Fundraising Fox
Kano Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 6 known investors
Find your way into Kano Therapeutics
Sign up to see every warm intro you have to Kano Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kano Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
Founders & leadership
Board
Investors · 6
How we know: Fifty Years's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Metaplanet's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Vsquared Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2024
▶$5MraisedMay 2024 · 4 investors · BiotechnologyRule 506(b)
- Ann DeWittDirector
- Floris EngelhardtExecutive Officer, Director
- John VroomDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Kano Therapeutics.
In the news
Frequently asked questions
- What does Kano Therapeutics do?
- Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
- Who are Kano Therapeutics's investors?
- Kano Therapeutics's investors include Fifty Years, Launchpad Venture Group, Metaplanet, The Engine Ventures, Vsquared Ventures, ZAKA VC.
- How much funding has Kano Therapeutics raised?
- Kano Therapeutics has disclosed $5M raised across 1 round.
- Where is Kano Therapeutics headquartered?
- Kano Therapeutics is headquartered in Cambridge, US.